Novel immunotherapies
- Elicio is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes .
- Our proprietary Amphiphile or “AMP” platform enables robust immune responses through smart trafficking to lymph nodes.
- Our focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be “activated” through lymph node trafficking.
